Profluent Bio vs Vivtex

Side-by-side comparison of AI visibility scores, market position, and capabilities

Vivtex leads in AI visibility (68 vs 37)
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile
Vivtex logo

Vivtex

ChallengerBioTech

Oral Biologics Drug Delivery

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

AI VisibilityBeta
Overall Score
B68
Category Rank
#1 of 1
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
66
Perplexity
63
Gemini
63

About

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

Full profile

AI Visibility Head-to-Head

37
Overall Score
68
#1
Category Rank
#1
69
AI Consensus
83
up
Trend
up
45
ChatGPT
66
35
Perplexity
63
38
Gemini
63
37
Claude
60
31
Grok
67

Key Details

Category
AI Protein Design
Oral Biologics Drug Delivery
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Profluent Bio
AI Protein Design
Only Vivtex
Oral Biologics Drug Delivery

Integrations

Only Vivtex

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.